Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

Analysis found adverse events of grade 3 or worse were reported in 36 (60%) of 60 patients with the most common being hypertension, fatigue, nausea, neutropenia, and vomiting. Also 25 (42%) patients reported ≥1serious adverse event, which most commonly was an infection (13%).


The Lancet Haematology